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Caring for Pregnant Women with Possible Zika Virus 
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July 27, 2017
Topics to be covered
• Updated interim guidance for pregnant women 
• Emerging data and current state of epidemic
• Updated recommendations for testing and interpretation of results 
• Pregnancy outcomes after maternal Zika virus exposure 
• Zika Pregnancy and Infant Registries
• Findings from the Zika Pregnancy and Infant Registries and implications
• Pediatric ophthalmologic findings among infants following congenital 
Zika virus infection 
• Ocular findings among infants with congenital Zika virus infection
• CDC guidance for ophthalmologic screening for infants with possible 
congenital infection 
Emerging Data and Current State of Epidemic
• Declining trend in reported cases of Zika infection leads to lower pretest probability 
and a higher proportion of positive test results being false
• Zika virus IgM antibodies can persist for months in some people, which could make 
it difficult for healthcare providers to use Zika IgM test results to determine 
whether an infection occurred during the current pregnancy versus prior to 
conception
Big Picture: Emerging Data and Implications for Zika Testing
Declining Trends in Reported Zika Cases in the Americas





PAHO Regional Zika Epidemiological Update (May 25, 2017): 
http://www.paho.org/hq/index.php?option=com_content&view=article&id=11599&Itemid=41691&lang=en 
Declining Trends in Reported Zika Virus Disease Cases in the US
Laboratory-confirmed Zika virus disease cases in US states and Washington, DC, 2016–
2017 (as of July 5, 2017)
2016 2017
Total Cases Reported
Hypothetical Example of Disease Prevalence and Implications for 
Test Performance : Disease is Common
Example 1: Disease is common
• 40 out of 100 patients in this 
area have the disease
• Test specificity: 98% (high) 
• Test sensitivity: 98% (high)
3% false positive
Hypothetical Example of Disease Prevalence and Implications for 
Test Performance : Disease is Rare
Example 2: Disease is rare
• 1 out of 100 patients in this 
area have the disease
• Test specificity: 98% (high) 
• Test sensitivity: 98% (high)
67% false positive
Prolonged Zika Virus IgM
• Zika virus IgM can persist beyond 12 weeks in a subset of 
infected people
• Unpublished preliminary data from Zika Virus Persistence (ZiPer) 
Study of persons with NAT-confirmed Zika virus disease 
• Zika virus IgM detected in 100% of participants at 8-15 days 
after symptom onset
• Detectable IgM levels decreased over time, however some 
participants remained IgM positive for more than 7 months 
after symptom onset
CDC HAN-00402: https://emergency.cdc.gov/han/han00402.asp 
Pregnant woman with possible exposure to Zika virus before current pregnancy
A positive Zika IgM antibody test 
result could mean….
Zika virus infection during current 
pregnancy, meaning pregnancy is 
likely at risk from Zika
Zika virus infection before current 
pregnancy, meaning pregnancy is 
likely not at risk from Zika
False positive result, meaning 
pregnancy is likely not at risk from 
Zika
Updated Guidance
Updated Guidance: Emphasis on Shared Decision-Making Model
• Updated guidance emphasizes a shared decision-making model for testing and screening 
pregnant women
• Clinical judgment is imperative
• Decisions about testing should be informed by factors such as 
• Length of possible exposure
• Type or location of travel 
• Intensity of Zika transmission 
• Presence of symptoms
• Prevention measures
• Preferences or concerns
• Jurisdictional recommendations
Symptomatic Pregnant Women with Possible Zika virus Exposure
Updated Guidance: Ask Pregnant Women 
ASK PREGNANT WOMEN about 
• Before and during current 
pregnancy: 
• Travel or residence in areas with 
risk for Zika virus transmission
• Possible sexual exposure
• Diagnosis of laboratory-confirmed 
Zika virus infection before the 
current pregnancy
• Symptoms of Zika virus infection 
during the current pregnancy
If no symptoms reported, refer to asymptomatic algorithm.
Updated Guidance: When to Test Symptomatic Pregnant Women 
WHEN to test?
Test as soon as 
possible; through 12
weeks after symptom 
onset
Updated Guidance: Which Tests for Symptomatic Pregnant Women 
WHICH tests?
Zika virus NAT* (serum and urine)
AND
Zika virus IgM serology (serum)
NAT = nucleic acid testing 
Updated Guidance: Test Results for Symptomatic Pregnant Women 
RESULTS & INTERPRETATION
Positive Zika virus NAT on serum 
and urine specimens 
ACUTE ZIKA VIRUS INFECTION
Interpretation of Results of Nucleic Acid and Antibody Testing for Suspected 
Zika Virus Infection
Oduyebo et al. Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus — United States, July 2017. https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s_cid=mm6629e1_w 
RESULTS & INTERPRETATION
Negative Zika virus NAT
AND
Negative Zika virus IgM
NO EVIDENCE OF ZIKA VIRUS 
INFECTION
Updated Guidance: Test Results for Symptomatic Pregnant Women  
Updated Guidance: Symptomatic Pregnant Women -- PRNT
RESULTS & ADDITIONAL TESTS
Negative Zika virus NAT
AND
Non-negative* Zika IgM 
Plaque reduction neutralization 
test (PRNT)
*Non-negative terms include positive, equivocal, presumptive positive, or possible. Terms listed here are only examples of assay interpretation 
terminology because nonnegative serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use 
for the specific assay performed. https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika
Updated Guidance: Symptomatic Pregnant Women 
RESULTS & INTERPRETATION
Zika virus PRNT >10 
AND
dengue virus PRNT<10
ZIKA VIRUS INFECTION, 
TIMING OF INFECTION CANNOT BE 
DETERMINED
For pregnant women without Zika virus exposure
before the current pregnancy, a positive IgM result
represents recent Zika virus infection.*
*For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus infection is defined as a possible exposure or infection 
during the current pregnancy or periconceptional period. 
Updated Guidance: Symptomatic Pregnant Women 
RESULTS & INTERPRETATION
Zika virus PRNT >10 AND dengue virus 
PRNT >10
FLAVIVIRUS INFECTION, 
SPECIFIC VIRUS AND TIMING OF 
INFECTON CANNOT BE DETERMINED
For pregnant women without Zika virus exposure 
before the current pregnancy, a positive IgM 
result represents recent unspecified flavivirus
infection.
*For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus infection is defined as a possible exposure or infection 
during the current pregnancy or periconceptional period. 
Updated Guidance: Symptomatic Pregnant Women 
RESULTS & INTERPRETATION
Zika virus PRNT <10
NO EVIDENCE OF ZIKA VIRUS 
INFECTION
Asymptomatic Pregnant Women with Possible Zika Virus Exposure
Updated Guidance: Asymptomatic Pregnant Women with Ongoing Possible 
Exposure
ASK PREGNANT WOMEN about 
• Possible Zika exposure before and 
during current pregnancy
• Diagnosis of laboratory-confirmed 
Zika virus infection before 
pregnancy
• Presence of symptoms during 
current pregnancy
COUNSEL PATIENTS on Zika testing
If symptoms are reported, refer to symptomatic algorithm.
Updated Guidance: Asymptomatic Pregnant Women with Ongoing 
Possible Exposure 
WHEN to test? WHICH tests?
Test with Zika virus NAT on 
serum and urine three times 
during pregnancy
Updated Guidance: Asymptomatic Pregnant Women with Ongoing 
Possible Exposure
REFER TO TABLE 1 FOR 
INTERPRETATION 
Updated Guidance: Asymptomatic Pregnant Women with Recent Possible 
Exposure, but without Ongoing Possible Exposure
Updated Guidance: Asymptomatic Pregnant Women with Recent Possible 
Exposure, but without Ongoing Possible Exposure 
WHOM to test
Testing is no longer routinely recommended. 
Testing should be considered using:
• A shared decision-making model based 
on patient preferences and values
• Clinical judgment
• A balanced assessment of risks and 
expected outcomes
• Jurisdiction’s recommendations
If testing is conducted, follow algorithm for symptomatic pregnant women using timeframe from last possible exposure. 
Initial Evaluation Of Infants Whose Mothers Had Possible Zika Virus 
Exposure During Pregnancy But Were Not Tested 
• Comprehensive physical exam
» Head circumference, weight, height measurements
» Neurologic assessment
• Standard newborn hearing assessment
• Based on level of possible exposure, consider
» Head ultrasound
» Ophthalmologic exam
• Based on evaluation, consider Zika virus laboratory testing of infant
https://www.cdc.gov/zika/hc-providers/infants-children/evaluation-testing.html 
Updated Guidance: Asymptomatic Pregnant Women with Possible Zika 
Virus Exposure
Jurisdictions may recommend testing of 
asymptomatic pregnant women for clinical 
decision-making or as part of Zika virus 
infection surveillance.
Updated Guidance: Testing of Placental and Fetal Tissues
Updated Guidance
Testing of placental tissues 
not routinely recommended 
for asymptomatic women 
without ongoing possible 
exposure when infant or 
fetus does not have Zika-
associated birth defects
Recommendations to Prevent Zika Virus Infection Have not Changed 
• Pregnant women should not travel to areas with 
risk for Zika virus transmission
Do Not Travel
• If a pregnant woman lives in or travels to an area 
with risk for Zika virus transmission, she should 
take steps to prevent mosquito bites
Prevent Mosquito Bites
• Take steps to prevent sexual transmission of Zika 
from a partner who  lives in or traveled to an area 
with risk for Zika virus transmission
Prevent Sexual 
Transmission
Clinical Tools for Implementing Guidance
Sharing Up-to-Date Information
• Providing updated clinical guidance
• Responding to your inquiries:
» Email: ZikaMCH@cdc.gov
» Zika Pregnancy Hotline: 770-488-7100
» CDC-INFO: (800-232-4636) 
http://www.cdc.gov/zika
CDC’S Response to Zika
Pregnancy Outcomes After Maternal Zika 
Virus Infection During Pregnancy — US 
Territories, January 1, 2016–April 25, 2017
US Zika Pregnancy Registry and Puerto Rico Zika Active 
Pregnancy Surveillance System
Dana Meaney-Delman, MD, MPH
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Centers for Disease Control and Prevention
Zika Pregnancy and Infant Registries: US Zika Pregnancy 
Registry and Zika Active Pregnancy Surveillance System 
(ZAPSS)
Purpose of registries
• To monitor pregnancy and infant outcomes in pregnancies 
with laboratory evidence of possible Zika virus infection 
• Estimate number of infants with birth defects
• Provide data to inform phenotype of congenital Zika syndrome
• Help ensure infants are linked to care 
Zika Pregnancy and Infant Registries: Who is Included
Pregnant women in the 50 US states and US territories. 
Pregnant women with laboratory evidence of possible Zika virus infection 
(regardless of whether they have symptoms) and their exposed infants.
Infants with laboratory evidence of congenital Zika virus infection (regardless of 
whether they have symptoms) and their mothers.
Zika Pregnancy and Infant Registries: A Comparison
Registry Feature
US Zika Pregnancy 
Registry
Zika Active Pregnancy 
Surveillance System 
Location 50 States and District of 
Columbia, US territories and 
Freely Associated States 
excluding Puerto Rico
Puerto Rico
Maternal Eligibility Pregnant women with 
laboratory evidence of Zika 
Pregnant women with 
laboratory evidence of Zika
Infant Follow-Up Through 1st year of life Through 3rd year of life
Pregnancy Outcomes Following Zika Virus Infection during 
Pregnancy in US Territories
• Provides data from women and infants living in American Samoa, the 
Commonwealth of Puerto Rico, the Federated States of Micronesia, the Republic 
of the Marshall Islands, and the US Virgin Islands
• Data reported to the US Zika Pregnancy Registry and the Puerto Rico Zika Active 
Pregnancy Surveillance System from January 1, 2016- April 25, 2017
Zika-Related Pregnancy Outcomes in US Territories









Results from Zika Pregnancy and Infant Registries 
Findings







% Symptomatic with birth defects 8 (4-13) 5 (4-6)
% Asymptomatic with birth defects 12 (7-19) 7 (4-11)
Birth Defects by Trimester of Infection at DX
First trimester 15 (8-26) 8 (5-12)
Second trimester -- 5 (4-7)
Third trimester -- 4 (3-6)
1. Reynolds MR, Jones AM, Petersen EE, et al. Vital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016. 
MMWR Morb Mortal Wkly Rep 2017;66:366-373. DOI: http://dx.doi.org/10.15585/mmwr.mm6613e1. 
2. Shapiro-Mendoza CK, Rice ME, Galang RR, et al. Pregnancy Outcomes After Maternal Zika Virus Infection During Pregnancy — U.S. Territories, January 1, 2016–April 25, 2017. MMWR Morb Mortal Wkly Rep 
2017;66:615-621. DOI: http://dx.doi.org/10.15585/mmwr.mm6623e1
Impact of Third Trimester Infections 
• 34% of 3rd trimester infections were symptomatic 
• Among mothers diagnosed with infection in the 3rd trimester, 4% had an 
infant or fetus with Zika virus-associated birth defects
Birth defects observed among pregnancies with 
symptom onset or positive laboratory testing during any 
trimester
Infant Follow-up in US Territories
Recommended infant 
screening and testing 
reported to Zika 












Infant Zika virus testing 55% 59% 59%
Postnatal neuroimaging 59% 52% 52%
Hearing screening 91% 78% 79%
Public Health Implications
• Highest proportion of Zika-associated birth defects among those with Zika 
virus infection during first and early second trimester of pregnancy
» More data are needed to explore whether women infected in the third 
trimester are at risk for:
• having a baby with birth defects 
• other adverse pregnancy outcomes
• Identification and follow-up care of infants can facilitate timely and 
appropriate clinical intervention services and assessment of future needs
• Monitoring of affected pregnancies and continued follow-up care for infants 
is critical to elucidating the impact of congenital Zika virus infection
What You Can Do to Help
Educate families on Zika virus prevention
Ask about possible Zika virus exposure
Provide all needed tests and follow-up care
Support infants and families
Report to the Zika virus pregnancy and infant registries
Summary 
• Zika virus infection diagnosed during any 
trimester of pregnancy poses a risk to the 
fetus 
• The absence or presence of symptoms in 
patients with confirmed Zika virus infection 
does not appear to affect the risk of birth 
defects 
• Healthcare providers can educate patients, 
follow CDC recommendations for screening 
and testing, support infants and families, and 
report to the Zika pregnancy and infant 
registries 
CDC’S Response to Zika
Zika Virus Infection:
Pediatric Ophthalmologic Findings 
S. Grace Prakalapakorn, MD, MPH
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Ocular Findings in Congenital Zika 
Infection 
Ocular Findings Associated with Congenital Zika Virus Infection 
• Ocular abnormalities have been identified in 
infants with and without microcephaly
• Abnormalities have been found in the 
anterior and posterior ocular structures
• Cortical visual impairment might be the most 
common cause of blindness among children 
with congenital Zika syndrome 
Macular and Optic Nerve Findings




Commonly reported optic 
nerve findings
• Hypoplasia







vascular tortuosity, abnormal vessel 
termination, and focal area of dilation
Ventura CV, et al. Ophthalmological findings in infants with microcephaly and presumable intra-uterus Zika virus infection. Arq Bras Oftalmol. 2016 Feb;79(1):1-3.
Miranda HA, et al. Expanded Spectrum of Congenital Ocular Findings in Microcephaly with Presumed Zika Infection. Ophthalmology. 2016 Aug;123(8):1788-94..




• Subluxation of the lens
• Cataract




de Paula Freitas, et al. Anterior-Segment Ocular Findings and Microphthalmia in Congenital Zika Syndrome. Ophthalmology. 2017 Jul. [Epub ahead of print]
Yepez JB, et al. Ophthalmic Manifestations of Congenital Zika Syndrome in Colombia and Venezuela. JAMA Ophthalmol. 2017 May 1;135(5):440-445
Risk Factors for Ocular Findings
• Smaller head circumference 
• Microcephaly
• Other CNS abnormalities
• Earlier trimester infection in pregnancy 
• Arthrogryposis
Ventura CV, et al. Risk Factors Associated With the Ophthalmoscopic Findings Identified in Infants With Presumed Zika Virus Congenital Infection. JAMA Ophthalmol. 2016 Aug 1;134(8):912-8.
Zin AA, et al. Screening Criteria for Ophthalmic Manifestations of Congenital Zika Virus Infection. JAMA Pediatr. 2017 Jul 17. [Epub ahead of print]
Moore CA, Staples JE, Dobyns WB, et al. Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatr 2017;171:288-95. 
Infants with Possible Zika Virus Infection WITHOUT Microcephaly
Hypopigmented retinal lesion Chorioretinal atrophy
-Ventura CV, et al. Zika: neurological and ocular findings in infant without microcephaly. Lancet. 2016 Jun 18;387(10037):2502. 
-Honein MA, Dawson AL, Petersen EE, et al. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. JAMA. 2017;317(1):59-68.
-Ventura CV, et al. First Travel-Associated Congenital Zika Syndrome in the US: Ocular and Neurological Findings in the Absence of Microcephaly. Ophthalmic Surg Lasers Imaging Retina. 2016 Oct 
1;47(10):952-955.
-de Paula Freitas, et al. Anterior-Segment Ocular Findings and Microphthalmia in Congenital Zika Syndrome. Ophthalmology. 2017 Jul. [Epub ahead of print
Eye findings in Infants Without CNS Abnormalities
Optic nerve hypoplasia, chorioretinal atrophy, 
and macular mottling 
Optic nerve hypoplasia and chorioretinal atrophy
Zin AA, et al. Screening Criteria for Ophthalmic Manifestations of Congenital Zika Virus Infection. JAMA Pediatr. 2017 Jul 17. [Epub ahead of print]
Eye Findings in Congenital Infections 
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+ + + + +
CDC Recommendations: Ophthalmic 
screening
Who should be referred for screening and when?
• Before hospital discharge:
» Infant whose mother has risk factors for maternal Zika virus infection (travel to or residence 
in an area with risk of Zika or sex with a partner who traveled to or resided in such an area) 
AND 
» Maternal test results are not available 
AND 
» There is a concern about infant follow-up care
• Before 1 month of age:
» All infants with laboratory evidence of congenital Zika virus infection
OR
» Abnormal findings consistent with CZS
• Follow up should occur 
» If the ophthalmologic examination within the first month of age is normal
» Another complete examination at 3 months of age
Russell K, Oliver SE, Lewis L, et al. Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection — United States, August 2016. MMWR 
Morb Mortal Wkly Rep 2016;65:870–878.
Screening should include
• Ophthalmologic assessment:
» Visual acuity assessment
» Intraocular pressure measurements
» Slit lamp examination
» Dilated fundus examination
• Resources for children with vision impairment or loss
» Low vision specialist
» Early intervention
National Eye Institute
How can primary care providers help?
• For infants without laboratory evidence of Zika virus infection but for whom suspicion for congenital 
Zika virus infection remains
» Consider referral to an ophthalmologist before hospital discharge or within 1 month of birth
• Outpatient management of infants with possible congenital Zika exposure but without abnormalities 
consistent with CZS
» During routine infant follow-up with primary care providers, at each well child visit
• Vision screening, including assessment of visual regard
• Referral to an ophthalmologist for any caregiver or provider concern
• Tips for screening vision in young infants
» For very young infants (1-2 months of age): test wince to light
» At about 3 months of age: fix and follow
» Test vision with both eyes open first, then try one eye at a time
Russell K, Oliver SE, Lewis L, et al. Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection — United States, August 2016. MMWR 
Morb Mortal Wkly Rep 2016;65:870–878.
Summary
• Declining transmission and new data on Zika virus persistence increase 
complexity of testing
• Updated guidance places emphasis on shared decision-making based on 
patient preferences, clinical judgment, and in line with jurisdictional 
recommendations
• Zika virus infection poses a risk to all pregnancies, regardless of timing of 
possible exposure and symptoms
• Congenital Zika virus infection can lead to poor ophthalmologic outcomes in 
the presence and absence of other birth defects  
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thank you!
More information on Zika: www.cdc.gov/zika
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)
Where:  On the COCA Call webpage 
https://emergency.cdc.gov/coca/calls/2017/callinfo_072717.asp
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All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and 
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continuing education  should complete the online evaluation by June 3, 
2017 with the course code WC2286. Those who will participate in the on 
demand activity and wish to receive continuing education should complete 
the online evaluation between June 3, 2017 and May 4, 2019 will use course 
code WD2286. 
Continuing education certificates can be printed immediately upon 
completion of your online evaluation. A cumulative transcript of all 
CDC/ATSDR CE’s obtained through the CDC Training & Continuing 
Education Online System will be maintained for each user. 
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